Galapagos' drug also active against Crohn's disease!

December 11, 2015 News BioVox

Galapagos has been working for a while on a drug, called Filgotinib, against rheumatoid arthritis. But this drug candidate also appears to have other therapeutic properties. Galapagos is now evaluating the drug against Crohn’s disease in a phase I clinical trial with 175 patients. The study showed a significantly higher clinical remission rate in patients treated with Filgotinib versus patients receiving the placebo and it was shown to be well tolerated.

These good results are a real boost for Galapagos, as it means that this drug also might be effective in other inflammatory diseases.  It strengthens the negotiation position of Galapagos. Initially, the biotech company had set up a partnership with AbbVie for ‘Filgotinib’, but that pharmaceutical company recently turned down the deal. Galapagos now might be able to enforce better conditions with another partner.


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts